Weiss Multi-Strategy Advisers’s Royalty Pharma RPRX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-41,894	Closed	-$1.76M	–	750
2022 Q2	$1.76M	Buy	+41,894	New	+$1.72M	0.05%	406
2020 Q3	–	Sell	-7,515	Closed	-$365K	–	666
2020 Q2	$365K	Buy	+7,515	New	+$372K	0.01%	486

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Weiss Multi-Strategy Advisers's RPRX Position: Q3 2022 in Review

Weiss Multi-Strategy Advisers sold out of Royalty Pharma (RPRX) in Q3 2022, closing a stake of 41,894 shares — an estimated $1.76M sold.

Weiss Multi-Strategy Advisers first reported a position in RPRX in Q2 2020 and held it in 2 quarters. The position peaked at $1.76M in Q2 2022. 319 funds tracked by Wall St. Rank hold RPRX as of Q3 2022.

Weiss Multi-Strategy Advisers reported no remaining Royalty Pharma position as of Q3 2022 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 41,894 Royalty Pharma shares in Q3 2022, an estimated $1.76M.
Weiss Multi-Strategy Advisers first reported a position in Royalty Pharma in Q2 2020 and held it in 2 quarters.
Weiss Multi-Strategy Advisers's Royalty Pharma position peaked at $1.76M in Q2 2022.
319 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2022.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.